company background image
D6M logo

genedrive DB:D6M Stock Report

Last Price

€0.0075

Market Cap

€11.8m

7D

-6.3%

1Y

-84.8%

Updated

04 Oct, 2024

Data

Company Financials

D6M Stock Overview

A molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications.

D6M fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

genedrive plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for genedrive
Historical stock prices
Current Share PriceUK£0.0075
52 Week HighUK£0.11
52 Week LowUK£0.002
Beta-0.038
11 Month Change-48.28%
3 Month Change66.67%
1 Year Change-84.85%
33 Year Change-96.65%
5 Year Changen/a
Change since IPO-99.56%

Recent News & Updates

Recent updates

Shareholder Returns

D6MDE Life SciencesDE Market
7D-6.3%-2.6%-1.0%
1Y-84.8%0.9%12.8%

Return vs Industry: D6M underperformed the German Life Sciences industry which returned 0.9% over the past year.

Return vs Market: D6M underperformed the German Market which returned 12.8% over the past year.

Price Volatility

Is D6M's price volatile compared to industry and market?
D6M volatility
D6M Average Weekly Movement47.7%
Life Sciences Industry Average Movement6.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: D6M's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: D6M's weekly volatility has decreased from 81% to 48% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200043Gino Mielewww.genedriveplc.com

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.

genedrive plc Fundamentals Summary

How do genedrive's earnings and revenue compare to its market cap?
D6M fundamental statistics
Market cap€11.83m
Earnings (TTM)-€5.97m
Revenue (TTM)€324.64k

36.4x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
D6M income statement (TTM)
RevenueUK£272.00k
Cost of RevenueUK£3.81m
Gross Profit-UK£3.54m
Other ExpensesUK£1.46m
Earnings-UK£5.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0092
Gross Margin-1,301.47%
Net Profit Margin-1,837.50%
Debt/Equity Ratio0%

How did D6M perform over the long term?

See historical performance and comparison